The C-C Motif Chemokine 2 pipeline drugs market research report outlays comprehensive information on the C-C Motif Chemokine 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the C-C Motif Chemokine 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Ophthalmology, and Gastrointestinal which include the indications Oncology, Ovarian Cancer, Dry (Atrophic) Macular Degeneration, Diabetic Retinopathy, Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It also reviews key players involved in C-C Motif Chemokine 2 targeted therapeutics development with respective active and dormant or discontinued products.
The C-C Motif Chemokine 2 pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 6, and 1 respectively.
C-C Motif Chemokine 2 overview
C-C Motif Chemokine 2 is a protein that in humans is encoded by a gene CCL2. It is also referred to as monocyte chemoattractant protein 1 (MCP1) and small inducible cytokine A2. These are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. This chemokine is a member of the CC subfamily which is characterized by two adjacent cysteine residues. This cytokine displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis, and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4.
For a complete picture of C-C Motif Chemokine 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
